Brexpiprazole-d8-1
Modify Date: 2024-01-30 00:58:29
Brexpiprazole-d8-1 structure
|
Common Name | Brexpiprazole-d8-1 | ||
|---|---|---|---|---|
| CAS Number | 1427049-19-1 | Molecular Weight | 441.62 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C25H19D8N3O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Brexpiprazole-d8-1Brexpiprazole-d8-1 is the deuterium labeled Brexpiprazole[1]. Brexpiprazole (OPC-34712), an atypical orally active antipsychotic drug, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[2][3]. |
| Name | Brexpiprazole-d8-1 |
|---|
| Description | Brexpiprazole-d8-1 is the deuterium labeled Brexpiprazole[1]. Brexpiprazole (OPC-34712), an atypical orally active antipsychotic drug, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
| References |
| Molecular Formula | C25H19D8N3O2S |
|---|---|
| Molecular Weight | 441.62 |